Stock AnalizAdma Biologics, Inc. ADMA
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Adma Biologics, Inc. (ADMA) is a healthcare company listed in the US with a market value of about $3.0B. In the twelve months to September 30, 2026 it had revenue of $519M and net income of $182M, a net margin of 35.1%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (2/5).
Key numbers: a P/E of 17.8, a price to free cash flow of 22.8, 5-year revenue growth of 65% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 36% below the current price.
Score: 2.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $519M | $510M | $426M | $258M | $154M | $81M | $42M | $29M | $17M | $23M | $11M |
| Net income | $182M | $147M | $198M | -$28M | -$66M | -$72M | -$76M | -$48M | -$66M | -$44M | -$20M |
| Free cash flow | $133M | $28M | $110M | $4M | -$73M | -$126M | -$115M | -$80M | -$65M | -$40M | -$18M |
| EPS (diluted) | $0.77 | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 | $-0.88 | $-0.89 | $-1.45 | $-1.91 | $-1.61 |
| Net margin | 35.1% | 28.8% | 46.4% | -10.9% | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% |
| ROIC | — | 27.6% | 25.5% | 7.8% | -12.8% | -18.9% | -26.6% | -34.1% | -103.1% | -47.3% | -124.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $18.00, 32% above the current price; targets range from $13.00 to $22.00; the consensus rating is “Buy”; expected EPS is $0.81 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Adma Biologics’s P/E ratio?
About 17.8, based on the last twelve months of diluted earnings per share (forward P/E about 16.0).
Is Adma Biologics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 36% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Adma Biologics pay a dividend?
Not currently.
Is Adma Biologics a good stock to buy?
We do not give buy or sell advice. Adma Biologics scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.